19/03/2004
Colostrinin™ – Other Potential Medical Uses
ReGen Therapeutics Plc (‘ReGen’ or the ‘Company’), a company developing Colostrinin™ as a potential treatment for Alzheimer’s disease announces, in response to questions from a number of sources, that:
Ongoing Mode of Action research* has suggested that Colostrinin™ may have efficacy in the prevention and/or treatment of other diseases including: Multiple Sclerosis, Parkinson’s Disease and Amyotrophic Lateral Sclerosis (Lou Gehrig’s Disease). Information on the mode of action of Colostrinin™ has been published.**
The Company wishes to make it quite clear that it has not, at this stage, conducted any specific research into the effect of Colostrinin™ on these diseases. In view of the significant degree of unmet medical need they represent it will consider research into these areas at the appropriate time, possibly in collaboration with a development partner.
Further information:
Andrew Marshall
Marshall Robinson Roe
Tel No: 020 7960 6007
* Most of this research has been conducted as part of ReGen’s ongoing collaboration with the University of Texas Medical Branch, Galveston, Texas, USA.
** I. Boldogh et al, Journal of Molecular Neuroscience, (2003), 20, 125-134